Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) Denkert C, Budczies J, Regan MM, Loibl S, Dell’Orto P, von Minckwitz G, Mastropasqua MG, et al. Journal article Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis (2019) Fasching P, Hartkopf AD, Gaß P, Häberle L, Akpolat-Basci L, Hein A, Volz B, et al. Journal article Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2018) Van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, et al. Journal article Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment (2018) Bauer ECA, Schochter F, Widschwendter P, Degregorio A, Andergassen U, Friedl TWP, Fasching P, et al. Journal article The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer (2018) Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching P, et al. Journal article The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer (2018) Brennan M, Gaß P, Häberle L, Wang D, Hartmann A, Lux MP, Beckmann M, et al. Journal article BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients (2018) Wunderle M, Gaß P, Häberle L, Flesch VM, Rauh C, Bani M, Hack C, et al. Journal article Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study (2017) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching P, Campone M, et al. Journal article A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (2017) Harbeck N, Saupe S, Jaeger E, Schmidt M, Kreienberg R, Mueller L, Otremba BJ, et al. Journal article Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis (2017) Hack C, Emons J, Jud S, Heusinger K, Adler W, Gaß P, Haeberle L, et al. Journal article